Compare Amylx Pharmaceuticals Inc (AMLX) vs Bath & Body Works Inc (BBWI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Bath & Body Works Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.37 (market cap $1.98B), while Bath & Body Works Inc trades at $20.65 (market cap $4.10B). The key difference: Bath & Body Works Inc is far larger — about 2.1× Amylx Pharmaceuticals Inc's market cap, and Bath & Body Works Inc pays a 3.94% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | BBWI | |
|---|---|---|
Market Cap | $1.98B | $4.10B |
Sector | Health | Consumer Cyclical |
52-Week High | $18.70 | $33.11 |
52-Week Low | $7.64 | $14.85 |
Enterprise Value | $1.70B | $7.99B |
Dividend Yield | — | 3.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
BBWI trades at $20.33, up 2.01% today, with a bearish technical signal but neutral oscillators. The stock shows strong profitability with a net margin of 10.03% and attractive valuation ratios, including a P/E of 5.78. Recent earnings beat expectations in Q1 2026, and the company's partnership with Ulta Beauty aims to expand reach. Cash flow trends indicate improving net cash flow by 2026, though the balance sheet carries significant debt.
The outlook is mixed: analyst consensus is a Buy with a $22.00 price target, suggesting upside, but risks include declining revenue over five years and high leverage. The Ulta partnership and cost-saving initiatives offer growth potential, yet competitive pressures and macroeconomic headwinds pose challenges for sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Bath & Body Works Inc
Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with less than 5% of sales from international markets in fiscal 2021. For fiscal 2021, 72% of sales stemmed from the brick-and-mortar network (which is composed of more than 1,700 retail stores), up from 65% in 2020, as consumer shopping patterns began to return to normal. Future growth is expected from store reformatting, digital and international channels, as well as new category expansion.
Read more on BBWI →
